Short Interest in Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) Increases By 51.0%

Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) was the recipient of a large growth in short interest during the month of July. As of July 31st, there was short interest totaling 16,586 shares, a growth of 51.0% from the July 15th total of 10,987 shares. Based on an average daily trading volume, of 80,891 shares, the short-interest ratio is presently 0.2 days. Approximately 3.3% of the shares of the company are short sold.

Analyst Upgrades and Downgrades

ELOX has been the subject of several recent research reports. Wall Street Zen raised Eloxx Pharmaceuticals to a “hold” rating in a report on Saturday, August 1st. Weiss Ratings assumed coverage on shares of Eloxx Pharmaceuticals in a research report on Friday. They set a “sell (d)” rating for the company. Lifesci Capital assumed coverage on shares of Eloxx Pharmaceuticals in a research note on Wednesday, July 22nd. They issued an “outperform” rating and a $40.00 target price for the company. Finally, Guggenheim assumed coverage on shares of Eloxx Pharmaceuticals in a research report on Monday, July 20th. They issued a “buy” rating and a $43.00 price target on the stock. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $41.50.

Eloxx Pharmaceuticals Stock Performance

Shares of Eloxx Pharmaceuticals stock traded down $1.47 during trading hours on Tuesday, reaching $17.00. The company had a trading volume of 11,416 shares, compared to its average volume of 54,988. Eloxx Pharmaceuticals has a one year low of $8.20 and a one year high of $19.96. The business has a fifty day moving average price of $13.77. The company has a market cap of $11.73 million, a price-to-earnings ratio of -1.11 and a beta of -1,863.11.

Eloxx Pharmaceuticals (NASDAQ:ELOX) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.66) earnings per share (EPS) for the quarter.

Eloxx Pharmaceuticals Company Profile

Eloxx Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company’s lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc, formerly known as Sevion Therapeutics Inc, is based in WALTHAM, United States.